Compounders Research Compare

NRx Pharmaceuticals, Inc.(NRXP)

Biotechnology · Wilmington, DE

$2.94+0.06 (+2.26%)

Delayed quote: Oct 6, 2026, 2:29 PM EDT

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Wilmington, DE

29 employees

www.nrxpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jonathan C. Javitt

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T18:32:22.949Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:32:22.949Z.

Quote observation: 2026-10-06T18:29:42.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 127,073,076
Total debt · period ending 2026-06-30: 1,246,000
Cash · period ending 2026-06-30: 26,686,000
TTM free cash flow · period ending 2026-06-30: -20,671,000

FMP input reference: 7a446221ee70341de49d615c46e15f9be625c30a72cedc9ff9e6473dbc59ae23

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NRXP EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

NRXP Competitors' EV/FCF Ratio

NRx Pharmaceuticals, Inc.

Current

Market Cap

$127.07M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Entera Bio Ltd.

Market Cap

$127.42M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Tonix Pharmaceuticals Holding Corp.

Market Cap

$125.65M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Pyxis Oncology, Inc.

Market Cap

$130.20M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TuHURA Biosciences, Inc.

Market Cap

$125.45M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cibus, Inc.

Market Cap

$122.13M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Health Catalyst, Inc.

Market Cap

$133.01M

EV/FCF Ratio

18.56x

TTM Avg

24.01x

3Y Avg

24.01x

5Y Avg

24.01x

Seer, Inc.

Market Cap

$121.23M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

enGene Holdings Inc.

Market Cap

$120.92M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AirSculpt Technologies, Inc.

Market Cap

$132.98M

EV/FCF Ratio

242.92x

TTM Avg

151.93x

3Y Avg

133.72x

5Y Avg

94.60x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
NRx Pharmaceuticals, Inc. (NRXP)	$127.07M	N/A	N/A	N/A	N/A
Entera Bio Ltd. (ENTX)vs ›	$127.42M	N/A	N/A	N/A	N/A
Tonix Pharmaceuticals Holding Corp. (TNXP)vs ›	$125.65M	N/A	N/A	N/A	N/A
Pyxis Oncology, Inc. (PYXS)vs ›	$130.20M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$125.45M	N/A	N/A	N/A	N/A
Cibus, Inc. (CBUS)vs ›	$122.13M	N/A	N/A	N/A	N/A
Health Catalyst, Inc. (HCAT)vs ›	$133.01M	18.56x	24.01x	24.01x	24.01x
Seer, Inc. (SEER)vs ›	$121.23M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$120.92M	N/A	N/A	N/A	N/A
AirSculpt Technologies, Inc. (AIRS)vs ›	$132.98M	242.92x	151.93x	133.72x	94.60x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics